Zervimesine Shows Promise in Dementia with Lewy Bodies
Cognition Therapeutics announced positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB) at the Alzheimer’s...
Jon Napitupulu
Voyager Adds Fourth Alzheimer’s Program to Pipeline
Voyager Therapeutics has expanded its Alzheimer’s disease pipeline with a new gene therapy program targeting APOE, the strongest genetic...
Sellas’ SLS009 Shows Promise in AML Phase 2 Trial, FDA Guides First-Line Study
SELLAS Life Sciences‘ Phase 2 trial of SLS009 (tambiciclib), a CDK9 inhibitor, for relapsed/refractory acute myeloid leukemia (r/r AML)...
Positive Phase 3 Obesity Trial Results for HRS9531 in China
Hengrui Pharma and Kailera Therapeutics announced positive topline data from a Phase 3 clinical trial of HRS9531/KAI-9531, a novel...
Mayo Clinic Joins Briacell’s Phase 3 Metastatic Breast Cancer Study
BriaCell Therapeutics has added Mayo Clinic as a clinical site for its ongoing Phase 3 clinical trial for Bria-IMT™,...
ProKidney and FDA Align on Rilparencel Accelerated Approval
ProKidney Corporation announced that the FDA has confirmed eGFR slope as an acceptable surrogate endpoint for the accelerated approval...
AAVB-039 FDA Clearance for Stargardt Disease Celeste Trial
AAVantgarde Bio received FDA clearance for its Investigational New Drug (IND) application for AAVB-039, a gene therapy for Stargardt...
Transcon® PTH Phase 3 Data Shows Sustained Response in Adults with Hypoparathyroidism
Ascendis Pharma released 3.5-year data from its Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism....
BiomX Initiates Phase 2b Trial of BX004 in Cystic Fibrosis Patients
BiomX Inc. initiated patient dosing in its Phase 2b trial for BX004, a phage therapy targeting antibiotic-resistant •Pseudomonas aeruginosa•...
Summit Max Clinical Trial Shows Real-World Results
Route 92 Medical announced positive real-world results for its HiPoint Reperfusion System, a catheter system used to treat acute...